LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. provided group earnings guidance for the six months ended June 30, 2024. The board of directors (the Directors) of the Company wishes to inform the shareholders of the Company (the Shareholders) and potential investors that based on the review of the Group's preliminary unaudited consolidated management accounts for the six months ended June 30, 2024 (the Reporting Period), the Group is expected to record a net profit attributable to owners of the Company ranging from approximately RMB 120 million to approximately RMB 150 million, which increased approximately 57.69% to 97.11% as compared that of RMB 76.1 million for the six months ended June 30, 2023. It is estimated that the non-IFRS profit is ranging from approximately RMB 130 million to approximately RMB 160 million, which increased approximately 50.29% to 84.97% as compared with that of approximately RMB 86.5 million for the six months ended June 30, 2023.

Based on currently available information, the expected increase in net profit attributable to the Shareholders was mainly due to the followings: Since obtaining the registration certificate from the National Medical Products Administration in September 2023, the Group ' s innovative product, MemoSorb ® Biodegradable patent foramen ovale occluder, has garnered high attention and enthusiastic reception from numerous patients due to its degradable technology. The product achieved rapid commercialization during the Reporting Period, thereby significantly increasing the Group' s revenue. This growth benefited from the Group ' s forward-looking research and development strategy, strong marketing capabilities, effective academic promotion, and well-established distribution network; and the Group's commercialization strategy for each of its innovative products is effectively implemented and has received positive results.

The MemoCarna® generation III congenital heart disease occluders, which are oxide coating occluders, have further increased the penetration rate in the PRC market. Sales performance of these products showed a significant improvement during the Reporting Period compared to the six months ended June 30, 2023.